Ritu Baral
Stock Analyst at TD Cowen
(0.69)
# 3,776
Out of 4,749 analysts
37
Total ratings
31.03%
Success rate
-22.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $9 | $7.25 | +24.14% | 6 | Nov 21, 2024 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $0.86 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.14 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $32.93 | +136.87% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $271.31 | +36.74% | 4 | Oct 21, 2024 | |
| INSM Insmed | Maintains: Buy | $75 → $98 | $76.58 | +27.97% | 3 | Aug 9, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $349 → $390 | $334.80 | +16.49% | 1 | Mar 15, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $4.40 | - | 1 | Aug 8, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $125 → $175 | $113.72 | +53.89% | 1 | Mar 22, 2023 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $32 → $21 | $18.66 | +12.54% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.38 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.86 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.60 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.55 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $37.28 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.46 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.75 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.29 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $652.18 | - | 2 | Jan 12, 2018 |
Sage Therapeutics
Nov 21, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $7.25
Upside: +24.14%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.86
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.14
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $32.93
Upside: +136.87%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $271.31
Upside: +36.74%
Insmed
Aug 9, 2024
Maintains: Buy
Price Target: $75 → $98
Current: $76.58
Upside: +27.97%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Outperform
Price Target: $349 → $390
Current: $334.80
Upside: +16.49%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $4.40
Upside: -
Sarepta Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $113.72
Upside: +53.89%
ACADIA Pharmaceuticals
Aug 8, 2022
Maintains: Outperform
Price Target: $32 → $21
Current: $18.66
Upside: +12.54%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.86
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.60
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.55
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $37.28
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.46
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $10.75
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $1.29
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $652.18
Upside: -